Evaluating, Scaling up and Enhancing Strategies for Supporting PrEP Continuation and Effective Use

In June 2019, the Prevention Product Manager (PMM)—a joint partnership between AVAC and the Clinton Health Access Initiative (CHAI)—and Jhpiego convened a think tank to consider how best to define and measure PrEP continuation. Its recommendations included modifying current PrEP indicators, recognizing that a single definition of correct or effective use might not be possible given fluctuating and variable HIV risk.

A second think tank was held in September 2020 with the theme Evaluating, Enhancing and Scaling up Strategies for Supporting PrEP Continuation and Effective Use. This think tank explored effective and promising strategies for helping people to stay on PrEP, strategies that can be scaled up across populations and locations.

CAB-LA is a Highly Effective HIV Prevention Option; Now what?

Long-acting injectable cabotegravir (CAB-LA) is a promising new option for HIV prevention. In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?

Broadly Neutralizing Antibody Combinations

As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.

AMP Study FAQ

From the two trial networks conducting the AMP Study, this document provides answers to commonly asked questions about the VRC01 antibody, details on the study design and more.

AVAC’s World AIDS Day 2020 Letter to the World

On World AIDS Day 2020, AVAC hones in on three things that are essential advocacy priorities for the present moment and in 2021.

• Program for choice.
• Pay for the healthcare workforce to achieve health equity.
• Pursue just, equitable access for COVID-19 vaccines, therapeutics and community-led prevention.

Biomedical HIV Prevention Trials: Results, milestones and more

This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.

Another version of this graphic is available here (same content, different visual Treatment U=U).

The Next-Generation of Biomedical Prevention: Now What

Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.

Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring

On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.

Global Investment in HIV Cure Research and Development in 2019

In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a

A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical

After decades of research and advocacy, the Dapivirine Vaginal Ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July, the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in the regulatory process to go forward. Download this podcast to hear five different perspectives on the ring, how it expands HIV prevention options for women, and the most important next steps to bring the ring to women who need it.